Imatinib, a potent tyrosine kinase inhibitor, is effluxed from cells by the breast cancer resistance protein (BCRP/ABCG2), yet published studies to date fail to demonstrate resistance to imatinib cytotoxicity in BCRP overexpressing cells in vitro. We investigated cellular resistance to imatinib in BCR-ABL expressing cells transduced and selected to overexpress BCRP (K562/BCRP-MX10). These cells exhibited a 2-to 3-fold increase in resistance to imatinib (P<0.05), and a 7-to 12-fold increase in resistance to mitoxantrone, a known BCRP substrate.
Introduction
Chronic myelogenous leukemia (CML) is a clonal disorder that arises by the translocation of chromosomes 9 and 22 in an early hematopoietic stem cell (HSC) to produce the Philadelphia chromosome (Ph). 1 This translocation results in production of the chimeric BCR-ABL protein, a constitutively active tyrosine kinase that drives hyperproliferation of stem and progenitor cells and the consequent panmyelosis associated with CML in the chronic phase of this disease. 2 Imatinib mesylate (STI571, or Gleevec) is a potent inhibitor of the BCR-ABL tyrosine kinase, and is cytotoxic to cells that are dependent on BCR-ABL kinase activity for growth and survival.
Accordingly, imatinib has proven to be highly effective in the treatment of the chronic phase of CML, with high rates of complete remission observed. 3 Unfortunately, molecular complete remissions evidenced by negative PCR reactions for BCR-ABL transcripts occur in only 35% of chronic phase cases treated with imatinib, 4 leading many to suspect that imatinib may not cure the majority of patients with chronic phase CML. 5 Primitive BCR-ABL expressing stem cells have been described in chronic phase CML that are resistant to the cytotoxic effects of imatinib, 6 leading some to postulate that this resistant, selfrenewing population could account for the failure of imatinib to cure the disease. Cellular resistance to imatinib can arise by a variety of mechanisms, including mutations in the BCR-ABL kinase, 7 and efflux by the multidrug resistance transporter, P-glycoprotein (P-gp). 8 Recently,
imatinib was found to be effluxed by another multidrug resistance transporter, the breast cancer resistance protein (BCRP, ABCG2). 9, 10 Since BCRP is expressed in primitive normal HSCs, 11 it is reasonable to posit the existence of counterpart BCR-ABL expressing HSCs in CML that express BCRP. These cells may contribute to the inherent imatinib resistance of these primitive CML
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Current published studies indicate a clear interaction of imatinib and BCRP. Imatinib stimulates BCRP-specific ATPase activity, 9 and is both a substrate and inhibitor of BCRP. 10, 12 Furthermore, imatinib bioavailability, pharmacokinetics, and disposition is influenced by BCRP, suggesting that BCRP functions as an imatinib transporter in vivo. 13, 14 Finally, chronic exposure of Caco2 cells to imatinib led to induction of BCRP expression. 15 To date, however, the only examination of the consequences of BCRP on imatinib cytotoxicity revealed no difference in the survival of Saos2 cells transfected to overexpress BCRP compared to controls. Here we report investigations of imatinib cytotoxicity in BCR-ABL-expressing K562
human CML cells that have been transduced and selected to express BCRP (K562/BCRP-MX10).
We find that K562 cells are sensitive to imatinib at nanomolar concentrations. K562/BCRP-MX10 cells are measurably resistant to imatinib cytotoxicity; however, this effect is attenuated by imatinib inhibition of BCR-ABL, which we find exerts a post-transcriptional enhancing effect on BCRP protein expression mediated by the phosphoinositol-3 kinase (PI3K)-Akt signaling pathway. In contrast to previous studies in mice, we find that inhibition of PI3K-Akt signaling in 20 In general, cells were washed with PBS, and then resuspended in growth media at an initial cell density of 0.5 x 10 5 cells/mL. Cells were continuously incubated at 37°C in an atmosphere of 5% CO 2 for three days. At the end of the experiment, an aliquot of each cell culture was stained with FDA (0.5 μg/mL) in a test tube at room temperature for 30 min, and then PI (50 μg/mL) was added to each tube. Cells were placed on ice until flow cytometric analysis. Cells that were FDA + and PI − were considered to be viable, and were counted. The XTT assay was performed using the Cell Proliferation Kit II (Roche Applied Science, Indianapolis IN). Cells were exposed continuously to mitoxantrone for 5 days or to imatinib for 3 days.
Cell proliferation assay
The effects of imatinib on cell proliferation were evaluated by counting cell numbers.
Generally, K562 and K562/BCRP-MX10 cells were washed with PBS twice, and then resuspended at initial density of 1.0 x 10 5 cells/mL in growth media or media including imatinib (0.1 µM) and/or FTC (5 µM). Cells were continuously exposed to imatinib and/or FTC for 5 days.
Cell numbers were determined with a Coulter Counter (Beckman-Coulter, Inc. Fullerton, CA) every day for up to 5 days.
Cellular surface expression of BCRP Cells were stained with PE-conjugated 5D3 antibody to BCRP (R&D Systems Inc. (Roche Applied Science), using an RNA amplification kit from Sigma. Primers for BCRP and β-actin were prepared as described previously. 24 The sequences of the primers for detecting MDR1 transcripts were as follows: sense: 5'-gtcacaatgcagacagc-3' and antisense: 5'-ccaacaacaaaataaggcca-3'. Data were analyzed described as previously.
Minneapolis MN). Generally cells were washed with phosphate buffered saline (PBS), and then
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Results
Selection of K562/BCRP with mitoxantrone
As received in our laboratory, K562/BCRP cells were only 5.5-fold resistant to mitoxantrone, and 1.3-fold resistant to imatinib. Hence, K562/BCRP cells were exposed to 10 nM mitoxantrone for 1 hour prior to each weekly passage to select cells with higher levels of BCRP and drug resistance. As shown in Figure 1A , BCRP protein expression was slightly greater than that of unselected K562/BCRP cells after 6 weeks of selection (P6), and was substantially greater after 15 weeks (P15). At this point, we stopped the selection process, and these cells were designated as K562/BCRP-MX10. During this selection process, no increase in hMDR1 mRNA ( Figure   1B ) or P-gp ( Figure 1C ) was observed.
Sensitivity of BCRP-expressing K562 cells to mitoxantrone and imatinib
To test the sensitivity of K562, K562/BCRP and K562/BCRP-MX10 cells to mitoxantrone and imatinib, cell viability was assessed by the FDA/PI method (Figure 2A Tables 1 and 2 . IC 50 values obtained with the XTT method were somewhat higher than those obtained with the FDA/PI method, but the relative resistance ratios for mitoxantrone or imatinib were similar between the two methods. K562/BCRP cells were 5.5-fold resistant to mitoxantrone compared to wild-type K562 cells (Table 1 ), in agreement with the original report. 16 Selection with mitoxantrone (K562/BCRP-MX10) increased mitoxantrone resistance to 7.2 fold by the FDA/PI assay ( Figure 2A , Table 1 ), with comparable relative levels of resistance (11.8-fold) detected by the XTT assay ( Figure 2C , Table 2 ). Similarly, K562/BCRP-MX10 cells were more resistant to imatinib than K562 wild-type cells determined by both cytotoxicity assays ( Figure 2B , To determine whether the resistance to imatinib is due to only BCRP overexpression, the effect of a specific inhibitor of BCRP, fumitremorgin-C (FTC), on resistance was studied in K562/BCRP-MX10 cells, with cellular viability assessed by the XTT assay ( Figure 2 C, D; Table   2 ). FTC (5 μM) completely sensitized K562/BCRP-MX10 cells to mitoxantrone and to imatinib; in contrast, FTC had no effect on mitoxantrone or imatinib cytotoxicity to wild-type K562 cells. form of p210 (b2a2, 68bp) and p230 (b19a2) so that we considered these products as non-related to BCR-ABL.
To rule out the possibility of upregulation of another molecular target of imatinib contributing to imatinib resistance in the K562/BCRP-MX10 cells, we measured the expression of cKit, a receptor tyrosine kinase that is known to activate the PI3K pathway and also a known target of imatinib. K562 wild-type cells have been reported to have very low expression of c-Kit protein. 26 Using Western blots, we were unable to detect any c-Kit protein in wild-type K562 or K562/BCRP-MX10 cells (data not shown). In contrast, strong and distinct immunoreactive bands of the characteristic molecular mass for c-Kit (120 and 145 kDa) were observed in two samples of human GIST tissue, which were studied as positive controls.
Taken together, the data in 
Effect of imatinib on BCRP expression
Cellular transformation by BCR-ABL is associated with high PI3K activity. 27, 28 Furthermore, it is known that murine Bcrp1 membrane localization and hence Bcrp1 function is regulated by PI3K-Akt signaling. 29 We therefore hypothesized that imatinib inhibition of BCR-ABL diminishes PI3K-Akt signaling, which may thereby diminish BCRP function in these K562 cells, resulting in less relative resistance to imatinib than to mitoxantrone. Indeed, 14 hr exposure 
Discussion
In the present work, we demonstrate that BCRP protects BCR-ABL + cells from the cytotoxicity of imatinib. However, we also find that BCR-ABL, by activation of the PI3K-Akt It is reasonable to believe that a Ph + counterpart to SP cells exists in cases of chronic phase CML.
Remarkably, quiescent self-renewing Ph + cells with stem cell characteristics have been described in patients with chronic phase CML, and these cells were found to be resistant to imatinib. 6 For
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Initially, this resistance was attributed to these cells being in a quiescent state; however, a more recent study finds no correlation between the cytotoxic activity of imatinib and proliferative status. 32 Hence, it is reasonable to postulate that these imatinib-resistant quiescent cells are BCRP- A potential concern with our methods is that the mitoxantrone selection we used to increase BCRP expression and drug resistance might provoke other mechanisms of resistance to imatinib, such as an increase in P-gp, which is reported to transport imatinib. 8 In the original description, K562/BCRP cells did not have high P-gp expression. 16 During the course of selection we did not observe any induction of MDR1 mRNA or P-gp protein as shown in Figure 1B , C.
Furthermore, we did not observe an increase in BCR-ABL mRNA or c-Kit protein as the result of mitoxantrone selection. Finally, the ability of the BCRP-specific inhibitor FTC to completely sensitize K562/BCRP-MX cells to imatinib as well as mitoxantrone, a key substrate for BCRP ( Figure 2C, D) , clearly indicates that BCRP is the cause of cytotoxic resistance to imatinib in these cells.
The BCR-ABL tyrosine kinase activates signal transduction pathways that stimulate growth and prevent apoptosis, such as JAK/STAT, Raf/MEK/ERK and PI3K/Akt, and confers cytokine-independent survival to hematopoietic cells. 28 Therefore, it is reasonable to find the PI3K/Akt pathway activated in K562 cells, and that phosphorylation of Ser 473 of Akt is diminished by imatinib treatment. 35 A number of reports indicate that the PI3K-Akt pathway is involved in post-transcriptional/post-translational modulation of BCRP. Bcrp1 protein expressed in murine hematopoietic SP cells was found to be translocated from the plasma membrane to the cytoplasm in Akt1 -/-mice or after exposure of wild type SP cells to LY294002, without a decrease in total Bcrp1 expression. 29, 36 In another study, BCRP expressed on the plasma membrane of guinea pig LLC-PK1 cells was internalized after treatment with LY294002 or wortmannin. 36 In our present study, overall BCRP protein was reduced significantly when K562/BCRP-MX10 cells were treated with imatinib or LY294002, both of which reduced phosphorylation of Akt (Figure 6 ), suggesting strongly that overall BCRP protein expression is regulated through the PI3K-Akt pathway. However, our findings in human leukemia cells clearly differ from the previous studies in murine or guinea pig cells, which show that PI3K-Akt signaling causes translocation of BCRP without loss of overall protein expression. 2) *** (p<0.001) 3) 21.3 ± 3.3 RT-PCR products from the indicated cells were visualized in 2% agarose gel, along with a 100 bp DNA ladder. 
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